RxDoctor Payments Data

Luis Galdamez, MD

General Practice · Huntington Park, CANPI 1679604417

Payments from drug & device makers

$1,613in general payments, 2019–2025

Across 51 payments — averaging $31.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$317
  • GSK$224
  • AstraZeneca$207
  • Novo Nordisk$170
  • Lilly USA, LLC$141
  • Roche Diagnostics Corporation$100
  • plus $454 from 12 others

What the payments were for

  • Food & beverage$1,613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,613 in reported general payments places this provider in the 85th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$21,497
Medicare patients
108
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate86$91,687
JardianceEmpagliflozin66$59,305
FarxigaDapagliflozin Propanediol41$41,415
EliquisApixaban32$35,523
OzempicSemaglutide25$21,602
TrulicityDulaglutide13$20,830
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$12,529
JanumetSitagliptin Phos/Metformin Hcl15$9,019
Tresiba Flextouch U-100Insulin Degludec16$7,038
Atorvastatin Calcium543$5,565
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$4,710
Albuterol Sulfate HfaAlbuterol Sulfate134$4,071
Losartan Potassium338$3,973
Metformin Hcl354$3,133
Tamsulosin Hcl123$2,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$34$100,706101 claims
AstraZenecaFarxiga$207$41,41541 claims
Novo NordiskOzempic$170$21,60225 claims
Lilly USA, LLCTrulicity$141$20,83013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 12,963 general practice providers in California.

Other general practice in Huntington Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →